about
Pandemrix™ and narcolepsy: A critical appraisal of the observational studies.Effect of the adjuvanted (AS03) A/H1N1 2009 pandemic influenza vaccine on the risk of rejection in solid organ transplant recipients in England: a self-controlled case seriesApplication of Probabilistic Multiple-Bias Analyses to a Cohort- and a Case-Control Study on the Association between Pandemrix™ and Narcolepsy.Adjuvanted (AS03) A/H1N1 2009 Pandemic Influenza Vaccines and Solid Organ Transplant Rejection: Systematic Signal Evaluation and Lessons Learnt.Epidemiology and costs of cervical cancer screening and cervical dysplasia in ItalyImpact of human papillomavirus-related genital diseases on quality of life and psychosocial wellbeing: results of an observational, health-related quality of life study in the UK.Infections, medication use, and the prevalence of symptoms of asthma, rhinitis, and eczema in childhood.Importance of feasibility assessments before implementing non-interventional pharmacoepidemiologic studies of vaccines: lessons learned and recommendations for future studies.A summary of the post-licensure surveillance initiatives for GARDASIL/SILGARD.Challenges in conducting post-authorisation safety studies (PASS): A vaccine manufacturer's view.Risk of solid organ transplant rejection following vaccination with seasonal trivalent inactivated influenza vaccines in England: A self-controlled case-series.Farm exposure in utero may protect against asthma, hay fever and eczema.Risk factors for respiratory syncytial virus bronchiolitis hospital admission in New Zealand.Distinct patterns of evolution between respiratory syncytial virus subgroups A and B from New Zealand isolates collected over thirty-seven years.Epidemiology and cost of treatment of genital warts in Spain.Incidence of invasive cervical cancer and direct costs associated with its management in Italy.Rotavirus hospitalisation in New Zealand children under 3 years of age.Treatment patterns and associated costs for genital warts in ItalyFrom genomics to surveillance, prevention and control: new challenges for the African meningitis beltSafety of AS03-adjuvanted influenza vaccines: A review of the evidence
P50
Q30379224-E29EE69A-BB1B-4FA2-9924-57086C2CB9BDQ30383985-2027A6D2-1B5C-4742-8F57-ECC9615353F2Q30384711-0364958E-AC25-4B6B-8228-2527CCCC0F1CQ30401136-CCA10142-24CB-40F9-A6B5-03D8D9E138CDQ33412571-7BADFE90-8C13-47C5-B532-5B14C9822CA6Q34478758-9DCFB4FA-362A-4DBA-BB18-B1971DA9A63DQ35572070-FCEA3C51-5BA1-42EA-B9E5-CF89CB182546Q37505531-DFE48B47-E022-408E-9E7D-9A84A95C71A2Q37745678-E6810113-8717-42AF-9EA8-171C50C2A912Q38808226-9B95500D-0B82-4E0A-909C-04F6FF0325E5Q39741902-4815308F-BA5A-4375-A4BB-1ACEAA83CEF3Q40420330-AEF74826-7F09-43F8-8F51-B4545AD83223Q45398006-000B3F3D-E609-44B6-BAE5-1B92FB97DE02Q45413095-D20196B0-D042-4A3A-AA2B-49056AE3DD11Q51126755-10945050-611E-4373-8369-05BB5EE58A4FQ51134207-127DC3AF-58ED-4F0D-A484-E7B0FF558D0DQ53256813-09009DD1-D902-452F-9B78-626A82D3A58FQ56833414-07FFF3A3-AE7F-42C1-93ED-1103005A81D9Q83971063-B77BB633-995F-485C-BEFB-D79D104980C6Q91577533-A6B1B22A-779D-45B4-BF62-4187F96CC9A9
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Catherine Cohet
@ast
Catherine Cohet
@en
Catherine Cohet
@es
Catherine Cohet
@nl
type
label
Catherine Cohet
@ast
Catherine Cohet
@en
Catherine Cohet
@es
Catherine Cohet
@nl
prefLabel
Catherine Cohet
@ast
Catherine Cohet
@en
Catherine Cohet
@es
Catherine Cohet
@nl
P106
P21
P31
P496
0000-0002-0022-7251